Which has preferable earnings and valuation, GMED or VCYT?

Globus Medical has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.71 $537.87M $3.91 20.75 Veracyte $517.15M 3.73 $66.35M $1.41 17.02

Does the media refer more to GMED or VCYT?

In the previous week, Globus Medical had 8 more articles in the media than Veracyte. MarketBeat recorded 31 mentions for Globus Medical and 23 mentions for Veracyte. Globus Medical's average media sentiment score of 0.64 beat Veracyte's score of 0.27 indicating that Globus Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 5 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 2 Very Positive mention(s) 4 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer WST or GMED?

In the previous week, Globus Medical had 5 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 31 mentions for Globus Medical and 26 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 0.75 beat Globus Medical's score of 0.64 indicating that West Pharmaceutical Services is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment West Pharmaceutical Services 10 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Globus Medical 5 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, GMED or RMD?

ResMed has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.71 $537.87M $3.91 20.75 ResMed $5.65B 5.95 $1.52B $10.98 21.80

Is GMED or RMD more profitable?

ResMed has a net margin of 27.79% compared to Globus Medical's net margin of 17.02%. ResMed's return on equity of 26.42% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 17.02% 14.57% 12.62% ResMed 27.79% 26.42% 19.43%

Does the media refer more to GMED or RMD?

In the previous week, ResMed had 4 more articles in the media than Globus Medical. MarketBeat recorded 35 mentions for ResMed and 31 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.64 beat ResMed's score of 0.55 indicating that Globus Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 5 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 6 Very Positive mention(s) 12 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GMED or GEHC?

In the previous week, Globus Medical had 5 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 31 mentions for Globus Medical and 26 mentions for GE HealthCare Technologies. GE HealthCare Technologies' average media sentiment score of 0.74 beat Globus Medical's score of 0.64 indicating that GE HealthCare Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 5 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GE HealthCare Technologies 10 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, DXCM or GMED?

DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 6.76 $836.30M $2.55 33.12 Globus Medical $2.94B 3.71 $537.87M $3.91 20.75

Is DXCM or GMED more profitable?

DexCom has a net margin of 19.42% compared to Globus Medical's net margin of 17.02%. DexCom's return on equity of 37.77% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 19.42% 37.77% 15.98% Globus Medical 17.02% 14.57% 12.62%

Does the media refer more to DXCM or GMED?

In the previous week, Globus Medical had 2 more articles in the media than DexCom. MarketBeat recorded 31 mentions for Globus Medical and 29 mentions for DexCom. DexCom's average media sentiment score of 0.96 beat Globus Medical's score of 0.64 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 15 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Globus Medical 5 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Globus Medical (GMED) Competitors

$71.56 -9.88 (-12.13%)

As of 03:07 PM Eastern

Compare

GMED vs. VCYT, WST, RMD, GEHC, and DXCM

Should you buy Globus Medical stock or one of its competitors? Globus Medical's main competitors and comparable companies include Veracyte (VCYT), West Pharmaceutical Services (WST), ResMed (RMD), GE HealthCare Technologies (GEHC), and DexCom (DXCM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Globus Medical compare to Veracyte?

Globus Medical (NYSE:GMED) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Globus Medical had 8 more articles in the media than Veracyte. MarketBeat recorded 31 mentions for Globus Medical and 23 mentions for Veracyte. Globus Medical's average media sentiment score of 0.64 beat Veracyte's score of 0.27 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	5 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	2 Very Positive mention(s)	4 Positive mention(s)	13 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veracyte has a net margin of 21.80% compared to Globus Medical's net margin of 17.02%. Globus Medical's return on equity of 14.57% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
Veracyte	21.80%	9.13%	8.53%

Globus Medical has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market.

Globus Medical has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.71	$537.87M	$3.91	20.75
Veracyte	$517.15M	3.73	$66.35M	$1.41	17.02

95.2% of Globus Medical shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by company insiders. Comparatively, 1.6% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Globus Medical currently has a consensus price target of $99.46, indicating a potential upside of 22.60%. Veracyte has a consensus price target of $51.40, indicating a potential upside of 114.17%. Given Veracyte's higher possible upside, analysts plainly believe Veracyte is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
Veracyte	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

Globus Medical beats Veracyte on 13 of the 17 factors compared between the two stocks.

How does Globus Medical compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and Globus Medical (NYSE:GMED) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by insiders. Comparatively, 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

West Pharmaceutical Services presently has a consensus target price of $424.67, indicating a potential upside of 8.14%. Globus Medical has a consensus target price of $99.46, indicating a potential upside of 22.60%. Given Globus Medical's higher probable upside, analysts clearly believe Globus Medical is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
West Pharmaceutical Services	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88

West Pharmaceutical Services has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Globus Medical has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Globus Medical has lower revenue, but higher earnings than West Pharmaceutical Services. Globus Medical is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
West Pharmaceutical Services	$3.40B	8.05	$493.70M	$8.91	44.07
Globus Medical	$2.94B	3.71	$537.87M	$3.91	20.75

In the previous week, Globus Medical had 5 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 31 mentions for Globus Medical and 26 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 0.75 beat Globus Medical's score of 0.64 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
West Pharmaceutical Services	10 Very Positive mention(s)	0 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	5 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

West Pharmaceutical Services has a net margin of 18.81% compared to Globus Medical's net margin of 17.02%. West Pharmaceutical Services' return on equity of 21.78% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
West Pharmaceutical Services	18.81%	21.78%	15.99%
Globus Medical	17.02%	14.57%	12.62%

Summary

West Pharmaceutical Services beats Globus Medical on 11 of the 17 factors compared between the two stocks.

How does Globus Medical compare to ResMed?

Globus Medical (NYSE:GMED) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Globus Medical has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, ResMed has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

ResMed has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.71	$537.87M	$3.91	20.75
ResMed	$5.65B	5.95	$1.52B	$10.98	21.80

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 18.4% of Globus Medical shares are held by company insiders. Comparatively, 0.6% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, ResMed had 4 more articles in the media than Globus Medical. MarketBeat recorded 35 mentions for ResMed and 31 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.64 beat ResMed's score of 0.55 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	5 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	6 Very Positive mention(s)	12 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical presently has a consensus price target of $99.46, indicating a potential upside of 22.60%. ResMed has a consensus price target of $253.69, indicating a potential upside of 6.01%. Given Globus Medical's stronger consensus rating and higher probable upside, analysts clearly believe Globus Medical is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
ResMed	0 Sell rating(s)	11 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.39

ResMed has a net margin of 27.79% compared to Globus Medical's net margin of 17.02%. ResMed's return on equity of 26.42% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
ResMed	27.79%	26.42%	19.43%

Summary

ResMed beats Globus Medical on 9 of the 17 factors compared between the two stocks.

How does Globus Medical compare to GE HealthCare Technologies?

Globus Medical (NYSE:GMED) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Globus Medical has a net margin of 17.02% compared to GE HealthCare Technologies' net margin of 9.96%. GE HealthCare Technologies' return on equity of 20.45% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
GE HealthCare Technologies	9.96%	20.45%	5.97%

Globus Medical has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Globus Medical currently has a consensus price target of $99.46, suggesting a potential upside of 22.60%. GE HealthCare Technologies has a consensus price target of $80.87, suggesting a potential downside of 3.47%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts clearly believe Globus Medical is more favorable than GE HealthCare Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
GE HealthCare Technologies	0 Sell rating(s)	11 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.52

GE HealthCare Technologies has higher revenue and earnings than Globus Medical. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.71	$537.87M	$3.91	20.75
GE HealthCare Technologies	$20.63B	1.84	$2.08B	$4.74	17.67

In the previous week, Globus Medical had 5 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 31 mentions for Globus Medical and 26 mentions for GE HealthCare Technologies. GE HealthCare Technologies' average media sentiment score of 0.74 beat Globus Medical's score of 0.64 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	5 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GE HealthCare Technologies	10 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Globus Medical beats GE HealthCare Technologies on 11 of the 17 factors compared between the two stocks.

How does Globus Medical compare to DexCom?

DexCom (NASDAQ:DXCM) and Globus Medical (NYSE:GMED) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.76	$836.30M	$2.55	33.12
Globus Medical	$2.94B	3.71	$537.87M	$3.91	20.75

DexCom has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Globus Medical has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

DexCom currently has a consensus target price of $95.50, indicating a potential upside of 13.07%. Globus Medical has a consensus target price of $99.46, indicating a potential upside of 22.60%. Given Globus Medical's higher probable upside, analysts clearly believe Globus Medical is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	0 Sell rating(s)	2 Hold rating(s)	24 Buy rating(s)	2 Strong Buy rating(s)	3.00
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88

In the previous week, Globus Medical had 2 more articles in the media than DexCom. MarketBeat recorded 31 mentions for Globus Medical and 29 mentions for DexCom. DexCom's average media sentiment score of 0.96 beat Globus Medical's score of 0.64 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	15 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	5 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.8% of DexCom shares are owned by institutional investors. Comparatively, 95.2% of Globus Medical shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 18.4% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

DexCom has a net margin of 19.42% compared to Globus Medical's net margin of 17.02%. DexCom's return on equity of 37.77% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.42%	37.77%	15.98%
Globus Medical	17.02%	14.57%	12.62%

Summary

DexCom beats Globus Medical on 12 of the 17 factors compared between the two stocks.

Get Globus Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMED vs. The Competition

Export

Metric	Globus Medical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$9.69B	$6.23B	$7.81B	$23.05B
Dividend Yield	N/A	1.69%	2.47%	3.69%
P/E Ratio	18.46	38.19	35.96	29.36
Price / Sales	3.29	5.14	8.55	3.12
Price / Cash	13.86	23.71	21.38	15.72
Price / Book	2.13	4.68	4.62	3.78
Net Income	$537.87M	$147.03M	$3.51B	$1.08B
7 Day Performance	-7.68%	-0.25%	-1.34%	-0.72%
1 Month Performance	-5.74%	-2.31%	-5.58%	-0.91%
1 Year Performance	16.40%	0.88%	2.15%	6.65%

Globus Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMED Globus Medical	4.4345 of 5 stars	$71.56 -12.1%	$96.46 +34.8%	+31.7%	$9.61B	$2.94B	18.30	6,000	Trending News Earnings Report Analyst Downgrade Insider Trade Gap Down High Trading Volume
VCYT Veracyte	4.0812 of 5 stars	$48.20 +0.6%	$55.78 +15.7%	-47.9%	$3.85B	$517.15M	31.53	755	Trending News Earnings Report Analyst Downgrade
WST West Pharmaceutical Services	3.7527 of 5 stars	$394.68 +0.6%	$391.17 -0.9%	+38.5%	$27.60B	$3.07B	50.53	10,800	Gap Up
RMD ResMed	4.3517 of 5 stars	$253.43 +0.2%	$243.23 -4.0%	-2.4%	$35.56B	$5.65B	22.64	11,370	Gap Down
GEHC GE HealthCare Technologies	3.3448 of 5 stars	$71.98 +0.7%	$78.35 +8.8%	+10.8%	$32.27B	$20.63B	16.51	54,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GMED) was last updated on 11/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Globus Medical (GMED) Competitors

GMED vs. VCYT, WST, RMD, GEHC, and DXCM

How does Globus Medical compare to Veracyte?

Summary

How does Globus Medical compare to West Pharmaceutical Services?

Summary

How does Globus Medical compare to ResMed?

Summary

How does Globus Medical compare to GE HealthCare Technologies?

Summary

How does Globus Medical compare to DexCom?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Globus Medical (GMED) Competitors

GMED vs. VCYT, WST, RMD, GEHC, and DXCM

How does Globus Medical compare to Veracyte?

Does the media refer more to GMED or VCYT?

Is GMED or VCYT more profitable?

Which has more risk and volatility, GMED or VCYT?

Which has preferable earnings and valuation, GMED or VCYT?

Do institutionals and insiders believe in GMED or VCYT?

Do analysts rate GMED or VCYT?

Summary

How does Globus Medical compare to West Pharmaceutical Services?

Do institutionals & insiders believe in WST or GMED?

Do analysts prefer WST or GMED?

Which has more volatility & risk, WST or GMED?

Which has better valuation & earnings, WST or GMED?

Does the media prefer WST or GMED?

Is WST or GMED more profitable?

Summary

How does Globus Medical compare to ResMed?

Which has more volatility and risk, GMED or RMD?

Which has stronger valuation & earnings, GMED or RMD?

Do insiders & institutionals hold more shares of GMED or RMD?

Does the media refer more to GMED or RMD?

Do analysts prefer GMED or RMD?

Is GMED or RMD more profitable?

Summary

How does Globus Medical compare to GE HealthCare Technologies?

Is GMED or GEHC more profitable?

Which has more risk and volatility, GMED or GEHC?

Do analysts rate GMED or GEHC?

Which has better valuation and earnings, GMED or GEHC?

Does the media favor GMED or GEHC?

Do insiders & institutionals hold more shares of GMED or GEHC?

Summary

How does Globus Medical compare to DexCom?

Which has stronger valuation & earnings, DXCM or GMED?

Which has more volatility and risk, DXCM or GMED?

Do analysts rate DXCM or GMED?

Does the media refer more to DXCM or GMED?

Do institutionals and insiders hold more shares of DXCM or GMED?

Is DXCM or GMED more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools